Acumen Pharmaceuticals Inc (ABOS NASDAQ) stock market data APIs
$2.5346
-0.02(-0.8%)
as of May 5, 2026
Try our APIs with
free plan!
Acumen Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer's disease. The company was incorporated in 1996 and is headquartered in Newton, Massachusetts.
Prev. Close
2.5346
Open
2.5116
High
2.5366
Low
2.4723
52 wk Range
0.959-3.6
Market Cap
179 M
Shares Outstanding
72 228 K
Revenue
329 K
EPS
-0.41
Beta
0.322
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Acumen Pharmaceuticals Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Acumen Pharmaceuticals Inc data using free add-ons & libraries
Get Acumen Pharmaceuticals Inc Fundamental Data
Acumen Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 329 K
- EBITDA: -123 774 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Acumen Pharmaceuticals Inc Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-03-30
- EPS/Forecast: -0.4558
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Acumen Pharmaceuticals Inc News
New
Acumen targets ALTITUDE-AD Phase II readout in late 2026 while advancing EBD program with $36M funding
Earnings Call Insights: Acumen Pharmaceuticals (ABOS) Q4 2025 MANAGEMENT VIEW * Daniel O'Connell, CEO, highlighted 2025 as "a year of execution and expansion at Acumen." He reported demonstrable p...
Pre-Market Earnings Report for March 26, 2026 : CMC, DOO, SCVL, DBI, LOVE, LUCD, ABOS, CGTX, RMTI
The following companies are expected to report earnings prior to market open on 03/26/2026. Visit our Earnings Calendar for a full list of expected earnings releases. Commercial Metals Company (CM...
Acumen Pharmaceuticals Raises $35.75 Million To Advance Alzheimer's Drug Programs
(RTTNews) - Acumen Pharmaceuticals, Inc. (ABOS) announced a $35.75 million private placement of its common stock at a price of $3.30 per share to support the development of its next generation of Alzh...
Acumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio
Financing demonstrates conviction in oligomer-selective approach and follows strong preclinical data, including in vitro, in vivo and non-human primate study results, that support development candidat...
Get Acumen Pharmaceuticals Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
